Advances in Immuno-Oncology: Considerations for the Use of Checkpoint Inhibitors Across Solid Tumours

Advances in Immuno-Oncology: Considerations for the Use of Checkpoint Inhibitors Across Solid Tumours is organized by Physicians' Education Resource, LLC (PER) and will be held from Nov 09, 2018 - Nov 09, 2019.

The target audience for this medical event is directed toward US & Ex-US medical oncologists, surgeons, pharmacists, physician assistants, and oncology nurses who treat or are involved in the treatment of patients with cancer. This CME Conference has been approved for a maximum of 1.5 Credits.

Description:
This activity, Advances in Immuno-Oncology: Considerations for the Use of Checkpoint Inhibitors Across Solid Tumours, will provide you with clinically important information about immune checkpoint inhibitors (ICPis) that you can use in the management of your patients with solid tumours. Listen to experts as they share clinical pearls regarding the incorporation of ICPis into their clinics. Topics will include the rationale for use of these agents, current and emerging strategies for selecting patients who can benefit from this approach, and placement of current data sets into the context of the treatment landscape. Moreover, you’ll learn about the identification, recognition, and management of immune-related toxicities. Start now to gain insights into this cutting-edge treatment approach.

Benefits of Completing Activity
Benefits of participating in the online activity, Advances in™ Immuno-Oncology: Considerations for the Use of Checkpoint Inhibitors Across Solid Tumours:
• Enhanced understanding of why immune checkpoint inhibitors (ICPis) are clinically important across a wide range of tumour types
• Improved competence of integrating ICPis into the management of your patients with solid tumours
• Increased ability to incorporate appropriate strategies to mitigate immune-related adverse events associated with ICPis
• Deepened knowledge of the clinical data sets supporting the use of ICPis, including in the management of brain metastases and as a part of combination approaches

Educational Objectives:
Upon completion of this activity, you should be better prepared to:
• Describe the rationale for the application of immunotherapeutic strategies to the management of solid tumors
• Discuss biomarkers and patient characteristics which may be used to identify patients who may benefit from the use of a checkpoint inhibitor, or be eligible for clinical trials evaluating novel immunotherapeutic strategies
• Apply clinical trial evidence to manage a variety of solid tumors in the context of evolving single-agent and combination immunotherapeutic strategies, including how these data may inform sequencing decisions
• Utilize evidence from clinical trials and practical experience to proactively identify and mitigate the impact of immune-related adverse events (irAEs) among patients who receive immunotherapeutic approaches to treat their cancer